Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce β-amyloid related to Alzheimer's disease
- 11 June 2010
- journal article
- review article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 391 (8), 861-872
- https://doi.org/10.1515/bc.2010.110
Abstract
Beta-amyloid (Aβ) in the brain is a major factor involved in Alzheimer's disease (AD) that results in severe memory deficit. Our recent studies demonstrate pharmacogenetic differences in the effects of inhibitors of cathepsin B to improve memory and reduce Aβ in different mouse models of AD. The inhibitors improve memory and reduce brain Aβ in mice expressing the wild-type (WT) β-secretase site of human APP, expressed in most AD patients. However, these inhibitors have no effect in mice expressing the rare Swedish (Swe) mutant amyloid precursor protein (APP). Knockout of the cathepsin B decreased brain Aβ in mice expressing WT APP, validating cathepsin B as the target. The specificity of cathepsin B to cleave the WT β-secretase site, but not the Swe mutant site, of APP for Aβ production explains the distinct inhibitor responses in the different AD mouse models. In contrast to cathepsin B, the BACE1 β-secretase prefers to cleave the Swe mutant site. Discussion of BACE1 data in the field indicate that they do not preclude cathepsin B as also being a β-secretase. Cathepsin B and BACE1 could participate jointly as β-secretases. Significantly, the majority of AD patients express WT APP and, therefore, inhibitors of cathepsin B represent candidate drugs for AD.Keywords
This publication has 45 references indexed in Scilit:
- An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine, 2009
- Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinBiochemical and Biophysical Research Communications, 2009
- Alternative pathways for production of β-amyloid peptides of Alzheimer's diseaseBiological Chemistry, 2008
- Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential β-secretasesBiological Chemistry, 2008
- Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivoNeuroscience Letters, 2008
- Alzheimer's diseaseThe Lancet, 2006
- The two sides of enzyme–substrate specificity: lessons from the aspartic proteinasesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitorJournal of Molecular Biology, 1992
- Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B, in vivoFEBS Letters, 1991
- In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64.Journal of Pharmacobio-Dynamics, 1986